COVID-19 is affecting the biopharma industry in myriad ways, including short-term disruption to R&D programs and clinical trials, but also causing complications in the commercial arena and to supply chains. As the immediate threat wanes and the new normal becomes more familiar, some of these enforced changes can be harnessed and adapted into longer-term strategies, particularly in light of the need to co-exist with the pandemic and societal changes.
Informa Connect Life Sciences and Pharma Intelligence are conducting a huge survey to gauge perspectives around deal-making during COVID-19 and the commercial ramifications of the pandemic. A particularly slow start to the year in terms of acquisitions is balanced by an extremely healthy environment for fundraising via public offerings and venture capital. This in turn will facilitate a large number of innovator companies and create new partnering, licensing and acquisition opportunities. Will the industry see much more in the way of collaboration and small-scale deal-making with these innovators, or will there be a return to consolidation and the large mega-blockbuster deals that the last decade ended with?
Completing the survey will give you exclusive early access to the final report, and all responses will remain anonymous. The data will also then be presented as part of a Pharma Intelligence webinar on October 7th.